A New CRISPR Tool Shreds Cancer Cell DNA Using the Tumor’s Own RNA as a Kill Switch

Roughly half of all cancers carry mutations in the p53 tumor suppressor protein, and for decades oncologists have had almost no way to drug them directly. A team at the Innovative Genomics Institute (IGI) at UC Berkeley, UC San Francisco, and the Gladstone Institutes may have found a workaround: instead of trying to fix the broken protein, they reprogrammed a bacterial CRISPR enzyme to read the mutant RNA transcript as a self-destruct signal, triggering widespread chromatin shredding inside the tumor cell and leaving the cell no way to survive.

CRISPR-Cas12a2 turns a cancer cell's RNA against itself

The tool at the center of this work is Cas12a2, a lesser-known cousin of the Cas9 enzyme that powers most CRISPR editing today. Where Cas9 binds complementary DNA and makes a single, precise cut, Cas12a2 binds complementary RNA and then, once activated, behaves more like a molecular paper shredder: it begins cleaving all nucleic acid material it encounters inside the cell. In bacteria, this response evolved as an abortive infection system, a scorched-earth tactic that sacrifices an infected cell to protect the colony. The IGI team asked whether the same logic could be applied to cancer.

The answer, at least in laboratory conditions, is yes. The researchers engineered guide RNAs complementary to cancer-specific mutant transcripts, including mutant p53 and KRAS sequences. When Cas12a2 encounters the matching RNA inside a tumor cell, it switches on, and the resulting chromatin demolition triggers DNA damage responses and ultimately cell death. Critically, Jingkun Zeng, one of the study authors, noted that adapting the system to a new mutation requires only designing a new guide RNA, a process that takes days rather than the years needed to develop a small molecule drug or antibody therapy.

Why undruggable p53 mutations make this approach significant

P53 is mutated in roughly 40 to 50 percent of all cancers and in 70 to 90 percent of some of the hardest-to-treat tumor types, including ovarian, pancreatic, and non-small cell lung cancers. The protein is a transcription factor, which means it lacks the defined binding pockets that most drugs exploit. Restoring its function has been called the holy grail of cancer therapy, but that grail has stayed frustratingly out of reach. Current precision oncology, despite its genuine advances, still leaves the majority of solid tumor patients without a genome-matched treatment option.

The Cas12a2 strategy sidesteps the binding-pocket problem entirely. It does not try to fix p53; it uses the mutant transcript as a flag that marks the cell for destruction. Jennifer Doudna, whose laboratory contributed to the work, framed the scope directly: "Not only can this approach target the 'undruggable' cancers that we know, we can also easily and quickly adapt this to new mutations. This is an exciting development for cancer therapies, and potentially for other applications as well."

Alan Ashworth, president of the UCSF Helen Diller Family Comprehensive Cancer Center, described the shift as a conceptual one: "This new approach reimagines how CRISPR can be used as a precision tool to find and eliminate cancer cells across a variety of cancer types. It may open up many new previously undruggable targets for cancer therapy."

Early results in cells and mice show selective killing

In cell culture experiments, the system reduced the growth of human lung cancer cells carrying KRAS mutations by 50 percent. It killed HPV-infected cells in a dish by more than 90 percent without harming healthy cells alongside them. In a mouse model, a single treatment reduced tumor volume by approximately 50 percent. The enzyme showed no detectable effect on cells carrying wild-type gene sequences, a specificity the authors describe as central to the approach's logic: the kill switch only fires when the cancer-specific RNA is present.

The team also demonstrated the principle against HPV- and HIV-infected cells, suggesting the mechanism is not limited to cancer. Any cell defined by a distinctive RNA signature could, in theory, be targeted.

Delivery and unknown in-vivo effects remain serious obstacles

This is investigational research, and the distance between a mouse result and a clinical trial is considerable. The most immediate problem is delivery. Cas12a2 is a large protein, and getting it into every tumor cell efficiently enough to produce a therapeutic effect in a living patient is a challenge the field has not yet solved. The broader landscape of RNA-based therapeutics faces similar hurdles: off-target effects, immune activation, manufacturing at scale, and effective delivery to tissues outside the liver are all active research problems without clean answers yet.

There are also questions specific to Cas12a2 that the authors acknowledge. The effects of the protein's presence in an organism, even when it is not activated, are currently unknown. The enzyme's activity depends on magnesium, and magnesium concentrations vary across different tumor microenvironments, which could introduce variability in how reliably it fires. Further testing in animal models is required before any human trials can be designed. The challenges facing RNA cancer therapeutics more broadly, including delivery efficiency and managing off-target effects, apply here as well, and none of them have been fully resolved.

Next steps toward combination therapy and new mutation targets

The researchers suggest that some cancers may eventually be treated with Cas12a2 as part of a combination regimen rather than as a standalone therapy. The speed with which new guide RNAs can be designed and tested means the platform could, in principle, keep pace with emerging resistance mutations more nimbly than conventional drug development allows. The growing optimism around RNA-interference-based approaches for solid tumors gives some reason to think the delivery challenges are solvable, though progress has been slower than early enthusiasm suggested.

For now, the work represents a genuine conceptual advance: proof that a cancer cell's molecular signature can be turned against it without touching the damaged protein directly. Whether that proof survives the translation from lab dish and mouse model to human biology will determine whether Cas12a2 joins the short list of CRISPR tools that have actually reached patients.

Evidence rating

INVESTIGATIONAL — 65/100

Caveats:

• Funding was not disclosed by the authors.
• Results are based on cell culture experiments and a single mouse model; human clinical trials have not begun.
• Delivery of the large Cas12a2 enzyme to all target cells in a living organism remains an unsolved challenge.
• The effects of Cas12a2 presence in an organism when not activated are currently unknown.
• This is a single study with no independent replication to date.

This is a proof-of-concept study combining in vitro cell culture experiments with a single mouse tumor model, with no human clinical data. The mechanistic causal chain is well-defined and the targeting specificity is clearly characterised, but the work has not been independently replicated and faces unresolved delivery challenges before clinical translation is possible. Findings are preliminary and should be interpreted as early-stage experimental evidence only.

References

1. Jingkun Zeng, Zhiyuan Cheng, Huadong Chen, et al. (2026). Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding. Nature. https://doi.org/10.1038/s41586-026-10738-7
2. Vitor Fiorin Vasconcellos, Leandro Machado Colli, Ahmad Awada, Gilberto de Castro Junior (2018). Precision oncology: as much expectations as limitations. ecancermedicalscience. https://doi.org/10.3332/ecancer.2018.ed86
3. Sarbjeet Kaur Makkar (2025). Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Frontiers in Genetics. https://doi.org/10.3389/fgene.2025.1675209
4. Evgenii Generalov, Alexei Shevelev, Dmitry Romanov, Olga Tarasova, Natalia Pozdniakova (2026). RNA Therapeutics in Viral Infections and Cancer: Mechanisms, Challenges, and Prospects: A Review. Pharmaceutics. https://doi.org/10.3390/pharmaceutics18040431
5. Manisit Das, Sara Musetti, Leaf Huang (2019). RNA Interference-Based Cancer Drugs: The Roadblocks, and the “Delivery” of the Promise. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2018.0762